CD163 expression defines specific, IRF8-dependent, immune-modulatory macrophages in the bone marrow.


Journal

The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002

Informations de publication

Date de publication:
11 2020
Historique:
received: 16 08 2019
revised: 13 01 2020
accepted: 11 02 2020
pubmed: 23 3 2020
medline: 16 3 2021
entrez: 23 3 2020
Statut: ppublish

Résumé

Scavenger receptor CD163 is exclusively expressed on monocytes/macrophages and is widely used as a marker for alternatively activated macrophages. However, the role of CD163 is not yet clear. We sought to examine the function of CD163 in steady-state as well as in sterile and infectious inflammation. Expression of CD163 was analyzed under normal and inflammatory conditions in mice. Functional relevance of CD163 was investigated in models of inflammation in wild-type and CD163 We describe a subpopulation of bone marrow-resident macrophages (BMRMs) characterized by a high expression of CD163 and functionally distinct from classical bone marrow-derived macrophages. Development of CD163 Our data indicate that anti-inflammatory and immunosuppressive mechanisms are not necessarily associated with a decreased antimicrobial activity. In contrast, our data define a novel macrophage population that controls overwhelming inflammation on one hand but is also necessary for an effective control of infections on the other hand.

Sections du résumé

BACKGROUND
Scavenger receptor CD163 is exclusively expressed on monocytes/macrophages and is widely used as a marker for alternatively activated macrophages. However, the role of CD163 is not yet clear.
OBJECTIVES
We sought to examine the function of CD163 in steady-state as well as in sterile and infectious inflammation.
METHODS
Expression of CD163 was analyzed under normal and inflammatory conditions in mice. Functional relevance of CD163 was investigated in models of inflammation in wild-type and CD163
RESULTS
We describe a subpopulation of bone marrow-resident macrophages (BMRMs) characterized by a high expression of CD163 and functionally distinct from classical bone marrow-derived macrophages. Development of CD163
CONCLUSIONS
Our data indicate that anti-inflammatory and immunosuppressive mechanisms are not necessarily associated with a decreased antimicrobial activity. In contrast, our data define a novel macrophage population that controls overwhelming inflammation on one hand but is also necessary for an effective control of infections on the other hand.

Identifiants

pubmed: 32199911
pii: S0091-6749(20)30344-4
doi: 10.1016/j.jaci.2020.02.034
pii:
doi:

Substances chimiques

Antigens, CD 0
Antigens, Differentiation, Myelomonocytic 0
CD163 antigen 0
Cytokines 0
Interferon Regulatory Factors 0
Receptors, Cell Surface 0
interferon regulatory factor-8 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1137-1151

Informations de copyright

Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Auteurs

Lena Fischer-Riepe (L)

Institute of Immunology, University of Muenster, Muenster, Germany.

Niklas Daber (N)

Institute of Immunology, University of Muenster, Muenster, Germany.

Jonas Schulte-Schrepping (J)

Genomics and Immunoregulation, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany.

Bruna Caroline Véras De Carvalho (BC)

Institute of Immunology, University of Muenster, Muenster, Germany.

Antonella Russo (A)

Institute of Immunology, University of Muenster, Muenster, Germany.

Michele Pohlen (M)

Institute of Immunology, University of Muenster, Muenster, Germany; Department of Medicine A, Hematology and Oncology, University Hospital of Muenster, Muenster, Germany.

Josephine Fischer (J)

Institute of Molecular Tumor Biology, University of Muenster, Muenster, Germany.

Achmet Imam Chasan (AI)

Institute of Immunology, University of Muenster, Muenster, Germany.

Marc Wolf (M)

Institute of Immunology, University of Muenster, Muenster, Germany.

Thomas Ulas (T)

Genomics and Immunoregulation, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany.

Shirin Glander (S)

Institute of Human Genetics, Genetic Epidemiology, University of Muenster, Muenster, Germany.

Christian Schulz (C)

Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.

Boris Skryabin (B)

Department of Medicine, Transgenic Animal and Genetic Engineering Models, University of Muenster, Muenster, Germany.

Andreas Wollbrink Dipl-Ing (A)

Institute for Biomagnetism and Biosignalanalysis, University of Muenster, Muenster, Germany.

Nadine Steingraeber (N)

Institute for Biomagnetism and Biosignalanalysis, University of Muenster, Muenster, Germany.

Christopher Stremmel (C)

Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany.

Megan Koehle (M)

Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany.

Florian Gärtner (F)

Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany.

Sabine Vettorazzi (S)

Institute of Comparative Molecular Endocrinology (CME), University of Ulm, Ulm, Germany.

Dirk Holzinger (D)

Institute of Immunology, University of Muenster, Muenster, Germany.

Joachim Gross (J)

Institute for Biomagnetism and Biosignalanalysis, University of Muenster, Muenster, Germany.

Frank Rosenbauer (F)

Institute of Molecular Tumor Biology, University of Muenster, Muenster, Germany.

Monika Stoll (M)

Institute of Human Genetics, Genetic Epidemiology, University of Muenster, Muenster, Germany.

Silke Niemann (S)

Institute of Medical Microbiology, University Hospital Muenster, Muenster, Germany.

Jan Tuckermann (J)

Institute of Comparative Molecular Endocrinology (CME), University of Ulm, Ulm, Germany.

Joachim L Schultze (JL)

Genomics and Immunoregulation, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany; Platform for Single Cell Genomics and Epigenomics (PRECISE) at the DZNE and the University of Bonn, Bonn, Germany.

Johannes Roth (J)

Institute of Immunology, University of Muenster, Muenster, Germany; Interdisciplinary Centre for Clinical Research, University of Muenster, Muenster, Germany.

Katarzyna Barczyk-Kahlert (K)

Institute of Immunology, University of Muenster, Muenster, Germany. Electronic address: bar@uni-muenster.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH